<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585246</url>
  </required_header>
  <id_info>
    <org_study_id>Application ID 213</org_study_id>
    <nct_id>NCT01585246</nct_id>
  </id_info>
  <brief_title>Saw Palmetto: Symptom Management for Men During Radiation Therapy</brief_title>
  <official_title>Saw Palmetto Use During Radiation Therapy for Symptom Management Among Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michigan State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test whether Saw Palmetto, is useful in preventing or reducing
      the side effects for men undergoing radiation therapy for prostate cancer. Urinary symptoms
      will be recorded each week, as well as assessment of quality of life through: 1) Physical
      Well-Being 2) Social/Family Well-being 3) Emotional Well-Being, and 4) Functional Well-Being.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lower urinary tract symptoms (LUTS) affect from 75-80% of men undergoing radiation therapy
      (RT) for prostate cancer. The purpose of this study was to determine the feasibility, safety
      and efficacy of inexpensive, non-toxic herbal supplement, Saw Palmetto (SP), in treating
      these distressing symptoms.

      The study consisted of two phases: Dose Finding phase (DFP), and Exploratory Randomized
      Controlled Trail (RCT) phase. In the 12 week DFP, participants were given one of three doses
      (SP 320 mg, SP 640mg, and SP 960 mg) using the Time-to-Event Continual Reassessment Method to
      determine the maximum therapeutic dose (MTD). Once the MTD was determined the RCT phase was
      begun, participants were allocated to receive either the predetermined MTD (960 mg) in the
      DFP or a placebo to obtain preliminary evidence of efficacy of SP on LUTS.

      Safety data consisted of the Common Terminology for Adverse Events criteria for nausea,
      gastritis, and anorexia. Efficacy of the MTD was evaluated by weekly symptom data and voiding
      diary. A pill diary was used to ensure the intervention fidelity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>Baseline to Week 12 for each phase.</time_frame>
    <description>Assess a Saw Palmetto supplementation protocol for feasibility by evaluation if at least 70% of eligible men consent, and if at least 70% of men enrolled at each dose complete the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>HRQOL: Baseline, week 12, 14, &amp; 22. IPSS: Baseline, week 3-12, 14, &amp; 22.</time_frame>
    <description>Evaluate preliminary efficacy of Saw Palmetto at the MTD as compared to the placebo group with respect to Health-Related Quality of life (HRQOL) including physical functioning and symptoms. The outcomes were measured using 1) the International Prostate Symptoms Score (IPSS) and 2) the total and subscales of the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The IPSS which ranges from 0-35. A lower score indicates better symptoms. The FACT-P has the following subscores and ranges: emotional well-being (0-24), functional well-being (0-28), physical well-being (0-28), social well-being (0-28), and prostate-specific concerns (0-48). The FACT-P total is comprised of the sum of the subscales and ranges from 0-156. For the FACT-P, a higher score indicates better quality of life. Each values was created as an average over time from a linear mixed effects model that adjusted for baseline values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Dose limiting toxicities was defined as the Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher for gastrointestinal symptoms (nausea, gastritis, anorexia). The maximum tolerated dose (MTD) was established among 320mg, 640mg,or 960mg, at which less than 10% of men report less than a grade 2 of gastrointestinal symptoms.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1: The dose finding phase (DFP)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: RCT phase- Saw Palmetto</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: RCT phase- Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received Soybean Oil Soft Gel as the placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saw Palmetto</intervention_name>
    <description>1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)</description>
    <arm_group_label>Phase 1: The dose finding phase (DFP)</arm_group_label>
    <arm_group_label>Phase 2: RCT phase- Saw Palmetto</arm_group_label>
    <other_name>SP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>soybean oil soft gel</intervention_name>
    <description>placebo (soybean oil soft gel)</description>
    <arm_group_label>Phase 2: RCT phase- Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 years or older

          -  Adenocarcinoma of the prostate

          -  Serum Prostate Specific Antigent (PSA) ≤ 40ng/ml

          -  Combined Gleason Score ≤ 8

          -  Karnofsky level of performance of &gt; 70%

          -  Consented to undergo definitive Radiation Therapy

        Exclusion Criteria:

          -  Stage T4 or M1

          -  Patient using own supply of Saw Palmetto or any other supplement containing the
             following herbs: Pygeum (African Plum), Urtica Dioica (Stinging nettle), Cucurbita
             peponis (pumpkin seed), PC-SPES (combination of 8 herbs), Beta-sitsterol (plant
             sterols) or Cernilton (rye grass pollen).

          -  Prior pelvic radiation therapy

          -  Abnormality in liver and kidney function as evidenced by greater than twice the normal
             values of Blood Urea Nitrogen (BUN), serum creatine, serum transaminases, and alkaline
             phosphatase.

          -  Uncontrolled hypertension despite use of antihypertensive medication

          -  Presence of major psychiatric or medical illness (e.g., major cardiovascular events
             within the previous 12 months)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwen Wyatt, PhD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>MichiganState University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allegiance Health</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Greater Lansing</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Macomb</name>
      <address>
        <city>Mount Clemens</city>
        <state>Michigan</state>
        <zip>48043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Central Michigan</name>
      <address>
        <city>Mount Pleasant</city>
        <state>Michigan</state>
        <zip>48858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Oakland Hospital</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <results_first_submitted>May 4, 2016</results_first_submitted>
  <results_first_submitted_qc>June 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2017</results_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Michigan State University</investigator_affiliation>
    <investigator_full_name>Gwen Wyatt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Symptom Management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saw palmetto extract</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase 1: Saw Palmetto Soft Gel 320mg/Day</title>
          <description>Participants in this arm received 320mg/day of Saw Palmetto Soft Gel capsules.</description>
        </group>
        <group group_id="P2">
          <title>Phase 1: Saw Palmentto Soft Gel 640mg/Day</title>
          <description>Participants in this arm received 640mg/day of Saw Palmetto Soft Gel capsules.</description>
        </group>
        <group group_id="P3">
          <title>Phase 1: Saw Palmetto Soft Gel 960mg/Day</title>
          <description>Participants in this arm received 960mg/day of Saw Palmetto Soft Gel capsules.</description>
        </group>
        <group group_id="P4">
          <title>Phase 2: RCT Phase- Saw Palmetto</title>
          <description>Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.</description>
        </group>
        <group group_id="P5">
          <title>Phase 2: RCT Phase- Placebo</title>
          <description>Patients received Soybean Oil Soft Gel as the placebo treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 1: Saw Palmetto Soft Gel 320mg/Day</title>
          <description>Participants in this arm received 320mg/day of Saw Palmetto Soft Gel capsules.</description>
        </group>
        <group group_id="B2">
          <title>Phase 1: Saw Palmetto Soft Gel 640mg/Day</title>
          <description>Participants in this arm received 640mg/day of Saw Palmetto Soft Gel capsules.</description>
        </group>
        <group group_id="B3">
          <title>Phase 1: Saw Palmetto Soft Gel 960mg/Day</title>
          <description>Participants in this arm received 960mg/day of Saw Palmetto Soft Gel capsules.</description>
        </group>
        <group group_id="B4">
          <title>Active Comparator: Phase 2: RCT Phase- Saw Palmetto</title>
          <description>Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg</description>
        </group>
        <group group_id="B5">
          <title>Placebo Comparator: Phase 2: RCT Phase- Placebo</title>
          <description>Patients received Soybean Oil Soft Gel as the placebo treatment</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="3.0"/>
                    <measurement group_id="B2" value="62.75" spread="12.09"/>
                    <measurement group_id="B3" value="62.1" spread="5.3"/>
                    <measurement group_id="B4" value="66.70" spread="11.30"/>
                    <measurement group_id="B5" value="67.82" spread="7.22"/>
                    <measurement group_id="B6" value="67.29" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility</title>
        <description>Assess a Saw Palmetto supplementation protocol for feasibility by evaluation if at least 70% of eligible men consent, and if at least 70% of men enrolled at each dose complete the study.</description>
        <time_frame>Baseline to Week 12 for each phase.</time_frame>
        <population>Number of men who started</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Men in 320mg/Day DFP</title>
            <description>Men assigned to the 320mg/Day group in the dose finding phase.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Men in 640mg/Day DFP</title>
            <description>Men assigned to the 640mg/Day group in the dose finding phase.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Men in 960mg/Day DFP</title>
            <description>Men assigned to the 960mg/Day group in the dose finding phase.</description>
          </group>
          <group group_id="O4">
            <title>Phase 2: Saw Palmetto 960 mg RCT</title>
            <description>Men assigned to the 960mg/Day of Saw Palmetto in the pilot RCT Phase</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: Placebo RCT</title>
            <description>Men assigned to the placebo in the pilot RCT Phase</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility</title>
          <description>Assess a Saw Palmetto supplementation protocol for feasibility by evaluation if at least 70% of eligible men consent, and if at least 70% of men enrolled at each dose complete the study.</description>
          <population>Number of men who started</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy</title>
        <description>Evaluate preliminary efficacy of Saw Palmetto at the MTD as compared to the placebo group with respect to Health-Related Quality of life (HRQOL) including physical functioning and symptoms. The outcomes were measured using 1) the International Prostate Symptoms Score (IPSS) and 2) the total and subscales of the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The IPSS which ranges from 0-35. A lower score indicates better symptoms. The FACT-P has the following subscores and ranges: emotional well-being (0-24), functional well-being (0-28), physical well-being (0-28), social well-being (0-28), and prostate-specific concerns (0-48). The FACT-P total is comprised of the sum of the subscales and ranges from 0-156. For the FACT-P, a higher score indicates better quality of life. Each values was created as an average over time from a linear mixed effects model that adjusted for baseline values.</description>
        <time_frame>HRQOL: Baseline, week 12, 14, &amp; 22. IPSS: Baseline, week 3-12, 14, &amp; 22.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: RCT Phase- Saw Palmetto</title>
            <description>Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.</description>
          </group>
          <group group_id="O2">
            <title>Phase 2: RCT Phase- Placebo</title>
            <description>Patients received Soybean Oil Soft Gel as the placebo treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy</title>
          <description>Evaluate preliminary efficacy of Saw Palmetto at the MTD as compared to the placebo group with respect to Health-Related Quality of life (HRQOL) including physical functioning and symptoms. The outcomes were measured using 1) the International Prostate Symptoms Score (IPSS) and 2) the total and subscales of the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The IPSS which ranges from 0-35. A lower score indicates better symptoms. The FACT-P has the following subscores and ranges: emotional well-being (0-24), functional well-being (0-28), physical well-being (0-28), social well-being (0-28), and prostate-specific concerns (0-48). The FACT-P total is comprised of the sum of the subscales and ranges from 0-156. For the FACT-P, a higher score indicates better quality of life. Each values was created as an average over time from a linear mixed effects model that adjusted for baseline values.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IPSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.54" spread="1.29"/>
                    <measurement group_id="O2" value="9.41" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-P total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.77" spread="4.37"/>
                    <measurement group_id="O2" value="124.48" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-P emotional well-being</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.77" spread="0.84"/>
                    <measurement group_id="O2" value="21.62" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-P functional well-being</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.24" spread="1.30"/>
                    <measurement group_id="O2" value="21.20" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-P physical well-being</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" spread="0.86"/>
                    <measurement group_id="O2" value="25.67" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-P social well-being</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.38" spread="1.08"/>
                    <measurement group_id="O2" value="21.02" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-P Prostate specific concern</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.13" spread="1.92"/>
                    <measurement group_id="O2" value="33.81" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose</title>
        <description>Dose limiting toxicities was defined as the Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher for gastrointestinal symptoms (nausea, gastritis, anorexia). The maximum tolerated dose (MTD) was established among 320mg, 640mg,or 960mg, at which less than 10% of men report less than a grade 2 of gastrointestinal symptoms.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Number of participants reporting adverse events at grade 2 or higher, according to the TITE-CRM algorithm</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Saw Palmetto Soft Gel 320mg/Day</title>
            <description>Participants in this arm received 320mg/day of Saw Palmetto Soft Gel capsules.</description>
          </group>
          <group group_id="O2">
            <title>Phase I: Saw Palmetto Soft Gel 640mg/Day</title>
            <description>Participants in this arm received 640mg/day of Saw Palmetto Soft Gel capsules.</description>
          </group>
          <group group_id="O3">
            <title>Phase I: Saw Palmetto Soft Gel 960mg/Day</title>
            <description>Participants in this arm received 960 mg/day of Saw Palmetto Soft Gel capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose</title>
          <description>Dose limiting toxicities was defined as the Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or higher for gastrointestinal symptoms (nausea, gastritis, anorexia). The maximum tolerated dose (MTD) was established among 320mg, 640mg,or 960mg, at which less than 10% of men report less than a grade 2 of gastrointestinal symptoms.</description>
          <population>Number of participants reporting adverse events at grade 2 or higher, according to the TITE-CRM algorithm</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The time-to-event continual reassessment method (TITE-CRM) was used The TITE-CRM incorporated a decision rule for the allocation of next participant to a dose of SP based on the current estimate of toxicity. The first men were allocated to lowest dose (320 mg); when no adverse event was reported during 12 weeks, the dose was increased to 640 mg for next men, and then to 960 mg in the absence of advert event.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Maximum Tolerated Dose (MTD)</param_type>
            <param_value>960</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were tracked with the Common Terminology Criteria for Adverse Events (CTCAE) at weeks 1 (baseline), 2-12, 14, 22 and 62.</time_frame>
      <desc>Adverse events were tracked with the Common Terminology Criteria for Adverse Events (CTCAE) including anorexia, nausea, gastritis, hematuria, hemorrhoids, diarrhea, proctitis, pruritis/itching, and fatigue.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1: The Dose Finding Phase (DFP)</title>
          <description>Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose.</description>
        </group>
        <group group_id="E2">
          <title>Phase 2: RCT Phase- Saw Palmetto</title>
          <description>Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960 mg.</description>
        </group>
        <group group_id="E3">
          <title>Phase 2: RCT Phase- Placebo</title>
          <description>Patients received Soybean Oil Soft Gel as the placebo treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gwen Wyatt</name_or_title>
      <organization>Michigan State University</organization>
      <phone>517-884-4630</phone>
      <email>gwyatt@msu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

